Condition
Multicentric Castleman Disease
Total Trials
4
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
300%
3 of 1 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Unknown1
Recruiting1
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04585893Phase 2Active Not RecruitingPrimary
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
NCT05663502Recruiting
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
NCT01441063Phase 2Completed
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
NCT03043105Phase 2UnknownPrimary
TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial
Showing all 4 trials